Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug calm the nosebleeds of a rare bleeding disorder?

NCT ID NCT07828015

Symptom relief Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Hereditary hemorrhagic telangiectasia (HHT) causes tangled blood vessels that lead to frequent, hard-to-stop nosebleeds and low hemoglobin. Researchers are testing whether intravenous bevacizumab, given once or twice a year after nasal electrocoagulation, reduces nosebleed severity and raises hemoglobin in 40 people with moderate-to-severe HHT. The study also tracks genetic and clinical factors that may explain why some patients respond better than others.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bevacizumab, an intravenous drug that blocks a blood-vessel growth signal
What this could lead to
If it works, bevacizumab could become a repeat infusion option that cuts severe nosebleeds and raises hemoglobin for people with HHT. Doctors might also learn which patients respond best.
What could go wrong
This is a small Phase 2 study of 40 people, so results may not hold in larger groups. Bevacizumab carries risks of bleeding, high blood pressure, and blood clots, and some patients may not respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Definite HHT diagnosis is established by either clinical assessment according to the Curaçao criteria or genetic confirmation. Clinical diagnosis (Curaçao criteria) Patients who meet at least 3 of the following 4 items are diagnosed with definite HHT: Spontaneous, recurrent epistaxis Multiple mucocutaneous telangiectasias at typical sites Visceral arteriovenous malformations (lung, liver, brain, gastrointestinal tract, etc.) Positive family history of HHT in a first-degree relative Genetic diagnosis Identification of a pathogenic germline mutation in HHT-associated genes (ENG, ACVRL1) confirms the diagnosis of HHT. Exclusion Criteria: * Minors, patients with mild epistaxis that can be well controlled by other treatments, and patients with any contraindication to bevacizumab treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bevacizimab are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary hemorrhagic telangiectasia telangiectasia, hereditary hemorrhagic, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bevacizimab HHT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.